Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.34 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.34 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 4/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457326 | 0.85 | LOXL2 (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1500761 | 0.83 | LOXL2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27719940 | 0.82 | LOXL2 (0.37) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL2301400 | 0.81 | FDPS (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19FDPS | |
| Trifluoromethanesulfonic Acid SCHEMBL30504299 | 0.74 | KIF11 (0.50) | ALDH1A1PLOD2PLOD3PLOD1NAMPT | |
| Trifluoromethanesulfonic Acid SCHEMBL5069402 | 0.74 | USP2 (0.45) | PLOD2PLOD3PLOD1NAMPTKIF11 | |
| Trifluoromethanesulfonic Acid SCHEMBL29252282 | 0.73 | SMN1; SMN2 (0.54) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL496725 | 0.73 | LOXL2 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19FDPS | |
| Trifluoromethanesulfonic Acid SCHEMBL2301996 | 0.72 | LMNA (0.44) | FDPSALDH1A1RAB9ALMNASMN1; SMN2 | |
| Trifluoromethanesulfonic Acid SCHEMBL3991498 | 0.72 | ALDH1A1 (0.38) | ALDH1A1PLOD2PLOD3PLOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-111247136-A | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating diseases and disorders associated with IRE1 | 吉宁特有限公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2018166528-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-4952397-A | HAVING PYRIDINIUM GROUP; ADMINISTERED WITH A DEHYDROPEPTIDASE INHIBITOR | MERCK & CO., INC. (US) | 1990-08-28 | — | — | US | disclosed |
| EP-0376355-A1 | 2-Quaternary heteroarylalkythio carbapenems | MERCK & CO. INC. (US) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | CYP1A2 431/4885CYP3A4 637/4885CYP2C9 1465/4885 |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | F12, F2, F11 | CYP1A2 153/4885CYP3A4 306/4885CYP2C9 103/4885 |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | CYP1A2 2494/4885CYP3A4 3196/4885CYP2C9 4487/4885 |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | XBP1, ERN1, ATF4 | CYP1A2 2494/4885CYP3A4 3196/4885CYP2C9 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.